title: Prostaglandin agonist effect on matrix metalloproteinase aqueous levels in glaucoma patients.
abstract: OBJECTIVE
  To determine whether the aqueous levels of matrix metalloproteinases (MMPs) differ between patients with glaucoma treated with topical prostaglandin analogues and normal, nonglaucomatous control patients. Also, to note any difference in MMP levels between latanoprost, travoprost, and bimatoprost that might suggest a difference in efficacy or mechanism of action between these drugs.
  
  
  METHODS
  Prospective, observational study.
  
  
  METHODS
  Patients who were scheduled to undergo routine intraocular surgery (phacoemulsification or combined phacotrabeculectomy) as part of their standard clinical care were included. Eighteen eyes of 18 patients with glaucoma using any 1 prostaglandin analogue (latanoprost, travoprost, or bimatoprost) were compared with 8 normal control patients.
  
  
  METHODS
  This was a multicentre study. Aqueous humour (0.2 mL) was aspirated at the beginning of the intraocular surgery through a clear corneal paracentesis. MMP-2 and -9 were quantified in the aqueous of all participants using enzyme-linked immunosorbent assay.
  
  
  RESULTS
  There was no significant difference in the levels of either MMP-2 (p = 0.216) or MMP-9 (p = 0.552) between the control patients and the patients with glaucoma on prostaglandins. There was no difference in the levels of MMP-2 or -9 between the latanoprost, travoprost, or bimatoprost groups.
  
  
  CONCLUSIONS
  The levels of MMP-2 and -9 in aqueous of glaucomatous eyes on topical prostaglandin analogues were the same as those of normal age-matched control patients. This could reflect either a return to normal levels with efficacious treatment or a lack of difference between disease and nondisease states.
authors: Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont.
authors: Zia Sultan
authors: ZS
authors: Pradhan
authors: Dr L H Hiranandani Hospital, Mumbai, India.
authors: Rajesh A
authors: RA
authors: Dalvi
authors: Royal Perth Hospital, Perth, Western Australia, Australia.
authors: Tze
authors: T
authors: Lai
authors: Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont.
authors: Christoph
authors: C
authors: Kranemann
authors: Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont.
authors: Shelley
authors: S
authors: Boyd
authors: Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont. Electronic address: catherine.birt@sunnybrook.ca.
authors: Catherine M
authors: CM
authors: Birt
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000201:enzymology*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D000077338:Latanoprost; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D000069557:Travoprost
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D000069580:Bimatoprost; D000069557:Travoprost